You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

1547 Results
Document
New
Nov 2025
Document
Document
New
Nov 2025
Document
New
Nov 2025
Document
Regimen
Cancer Type:
Gastrointestinal, 
Gastric / Stomach
Intent: Palliative
Funding:
New Drug Funding Program
    Zolbetuximab - First-line Treatment of Advanced Gastric and Gastroesophageal Junction Adenocarcinoma
Nov 2025
Regimen
Cancer Type:
Gastrointestinal, 
Gastric / Stomach
Intent: Palliative
Funding:
New Drug Funding Program
    Zolbetuximab - First-line Treatment of Advanced Gastric and Gastroesophageal Junction Adenocarcinoma
Nov 2025
Regimen
Cancer Type:
Gastrointestinal, 
Gastric / Stomach
Intent: Palliative
Funding:
New Drug Funding Program
    Zolbetuximab - First-line Treatment of Advanced Gastric and Gastroesophageal Junction Adenocarcinoma
ODB - General Benefit
    capecitabine
Nov 2025
Regimen
Cancer Type:
Gastrointestinal, 
Gastric / Stomach
Intent: Palliative
Funding:
New Drug Funding Program
    Zolbetuximab - First-line Treatment of Advanced Gastric and Gastroesophageal Junction Adenocarcinoma
ODB - General Benefit
    capecitabine
Nov 2025

Pages